Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Intermediate Risk Prostate Cancer × 1 year × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 2774 Neoplasms 2245 Carcinoma, Non-Small-Cell Lung 1689 Prostatic Neoplasms 1510 Colorectal Neoplasms 1233 Lung Neoplasms 1151 Multiple Myeloma 852 Neoplasm Metastasis 827 Leukemia, Myeloid, Acute 795 Pancreatic Neoplasms 771 Ovarian Neoplasms 726 Melanoma 712 Carcinoma, Hepatocellular 663 Recurrence 584 Brain Neoplasms 579 Stomach Neoplasms 575 Squamous Cell Carcinoma of Head and Neck 575 Head and Neck Neoplasms 518 Lymphoma 501 Glioblastoma 501 Uterine Cervical Neoplasms 482 Precursor Cell Lymphoblastic Leukemia-Lymphoma 473 Carcinoma, Renal Cell 457 Triple Negative Breast Neoplasms 448 Endometrial Neoplasms 428 Colonic Neoplasms 420 Urinary Bladder Neoplasms 417 Hematologic Neoplasms 412 Lymphoma, Non-Hodgkin 400 Sarcoma 387

Interventions

spartalizumab 1 Nivolumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03815942 2025-06-25

ADVANCE

University of Oxford

Phase 1/2 Terminated

23 enrolled 11 charts

Intermediate Risk Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡